The FDA has cleared Ultherapy PRIME, Merz's microfocused ultrasound (MFU) device, for skin laxity on the knees. The clearance expands the platform beyond facial and neck applications into a high-demand body-sculpting zone—knees rank among the top aesthetic concerns for patients seeking non-invasive tightening without downtime.
Devices & Tech
FDA Clears Ultherapy PRIME for Knee Skin Laxity
Merz's microfocused ultrasound expands into body-contouring indication.
Knee treatments command $2,000–$4,000 per session depending on market.
Ultherapy PRIME delivers focused ultrasonic energy at precise depths (1.5 mm, 3.0 mm, 4.5 mm) to trigger collagen remodeling and neocollagenesis. Knee treatment typically requires 1–2 sessions spaced 3–6 months apart. The indication opens a new revenue stream for practices already operating Ultherapy for facial work—knee treatments command $2,000–$4,000 per session depending on market and practice positioning. This complements body-contouring demand driven by GLP-1 patient interest in post-weight-loss skin tightening.
Source: original report ↗
Free alerts
Free: recall & rule-change alerts for your practice.
Get the recalls and state-law changes that hit your treatment room, in your inbox — free. Unsubscribe in one click.
Free · weekly · unsubscribe anytime. Privacy.
Stay three moves ahead of every practice in your market.
Knowing it happened is table stakes. Inside MedSpa Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief, twice a week. The owners who read it never get blindsided.
Get the edge · $20/moJoin the owners who run ahead of the industry. Cancel anytime, one click.